Correlation between CYP2B6 exonic gene polymorphisms and efavirenz plasma concentrations in Yi ethnic HIV/AIDS patients: a study from Sichuan province, China
5 affiliations
- 1Department of Infectious Disease, Sichuan Provincial People’ s Hospital, University of Electronic Science and Technology of China, Chengdu, China
- 2Institute of Infectious Diseases, Southwest Hospital of Army Medical University, Chongqing Key Laboratory of Infectious Disease Research, Chongqing, China
- 3Infectious Diseases Department of Bazhong Central Hospital, Bazhong, Sichuan China
- 4Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Department of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People’ s Hospital, University of Electronic Science and Technology of China, Chengdu, China
- 5Department of Nephrology, Sichuan Provincial People’ s Hospital, University of Electronic Science and Technology of China, Chengdu, China
Abstract
Background: Polymorphisms in the CYP2B6 Gene significantly impact efavirenz (EFV) metabolism and plasma levels, resulting in variability in both treatment effectiveness and toxicity among individuals. In this study, we aimed to evaluate the relationship between the CYP2B6 polymorphisms and the plasma concentrations of EFV for Yi ethnic HIV positive individuals residing in the province of Sichuan, China.
Methods: The study consisted of 94 Yi HIV patients receiving antiretroviral therapy (ART) based on efavirenz. All patients had their plasma levels of efavirenz measured, and CYP2B6 gene polymorphisms were detected through sequencing of the gene; statistical analysis, including Chi-square tests, established the relationship between genotype and plasma concentrations of efavirenz and classified those concentrations into therapeutic (1000–4000 ng/mL) and supratherapeutic (> 4000 ng/mL).
Results: The median level of EFV in the Yi population was 2550 ng/mL (IQR: 2015–3491.5 ng/mL), with a range of 1009.5-19100 ng/mL. Five polymorphisms in the CYP2B6 gene were identified: 516G > T (allele frequency 0.25), 785A > G (0.3), 1138T > C (0.01), 64C > T (0.03), and 370C > T (0.01). The results showed significant differences in the concentration of EFV based on 516G > T, where the percentage of patients with supratherapeutic concentrations (> 4000 ng/mL) was higher among TT genotype carriers than among wild-type carriers (χ² = 17.00, p = 0.001); 71.43% of patients with the TT genotype had concentrations above 4000 ng/mL compared to only 10.34% of patients with the GG wild-type genotype. The data on the 785A > G variant show that 41.67% of GG carriers had concentrations above 4000 ng/mL, compared with only 12.24% of patients with the AA wild-type genotype.
Discussion: CYP2B6 polymorphisms, specifically the 516G > T and 785A > G, had a major impact on the pharmacokinetics of EFV and therefore led to an increase in plasma concentrations of efavirenz among Yi HIV/AIDS patients. The results also support findings from other studies worldwide that associate these same polymorphisms with decreased enzyme activity and thus decreased ability to metabolize EFV. The unique genetic background of the Yi population underscores the importance of using pharmacogenomics tools specifically designed for this population.
Conclusion: CYP2B6 polymorphisms, including specifically the 516G > T variant, are important predictors of plasma concentrations of EFV among Yi HIV positive patients. The 785A > G variant also predicts a higher percentage of patients exceeding the supratherapeutic range and does not affect median plasma concentrations. Dose adjustment guided by genotype may increase treatment response and decrease adverse events in this ethnic population.
Clinical trial number: Not applicable.
Related
- Vitamin D Receptor Polymorphisms Are Associated with 25(OH)D3 Concentrations and Systemic Inflammation in Decompensated Cirrhosis
- Association Between Serum Folate Concentrations and Dyslipidemia Among Children and Adolescents in Zhejiang Province, China: A Cross-Sectional Study
- Correlation analysis between hand hygiene product consumption trends and healthcare-associated infections in a tertiary comprehensive hospital in Yunnan Province, China (2015–2024)
- Genetic Polymorphisms and Hemostatic-Inflammatory Biomarkers in Schizophrenia Patients Receiving Antipsychotic Treatment
- Association analysis of IL-6 polymorphisms and relevant biomarkers in patients with renal failure
BibTeX
@article{wang2026correlation,
title = {{Correlation between CYP2B6 exonic gene polymorphisms and efavirenz plasma concentrations in Yi ethnic HIV/AIDS patients: a study from Sichuan province, China}},
author = {Shuqiang Wang and Cheng Yang and Yajun Shi and Kaiju Xu and Liting Yan and Tingting Luo and Lin Tuo and Renguo Yang and Qiaoling Zhou and Yongquan He and Lulin Huang and Weiwei He and Jiazhen Wu and Ying Liu and Yanan Chen and Xingxiang Yang},
journal = {BMC Infectious Diseases},
year = {2026},
month = aug,
doi = {10.1186/s12879-026-13490-5},
url = {https://doi.org/10.1186/s12879-026-13490-5},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Correlation between CYP2B6 exonic gene polymorphisms and efavirenz plasma concentrations in Yi ethnic HIV/AIDS patients: a study from Sichuan province, China
AU - Shuqiang Wang
AU - Cheng Yang
AU - Yajun Shi
AU - Kaiju Xu
AU - Liting Yan
AU - Tingting Luo
AU - Lin Tuo
AU - Renguo Yang
AU - Qiaoling Zhou
AU - Yongquan He
AU - Lulin Huang
AU - Weiwei He
AU - Jiazhen Wu
AU - Ying Liu
AU - Yanan Chen
AU - Xingxiang Yang
PY - 2026
DA - 2026/08/14
JO - BMC Infectious Diseases
DO - 10.1186/s12879-026-13490-5
UR - https://doi.org/10.1186/s12879-026-13490-5
AB - Background: Polymorphisms in the CYP2B6 Gene significantly impact efavirenz (EFV) metabolism and plasma levels, resulting in variability in both treatment effectiveness and toxicity among individuals. In this study, we aimed to evaluate the relationship between the CYP2B6 polymorphisms and the plasma concentrations of EFV for Yi ethnic HIV positive individuals residing in the province of Sichuan, China. Methods: The study consisted of 94 Yi HIV patients receiving antiretroviral therapy (ART) based on efavirenz. All patients had their plasma levels of efavirenz measured, and CYP2B6 gene polymorphisms were detected through sequencing of the gene; statistical analysis, including Chi-square tests, established the relationship between genotype and plasma concentrations of efavirenz and classified those concentrations into therapeutic (1000–4000 ng/mL) and supratherapeutic (> 4000 ng/mL). Results: The median level of EFV in the Yi population was 2550 ng/mL (IQR: 2015–3491.5 ng/mL), with a range of 1009.5-19100 ng/mL. Five polymorphisms in the CYP2B6 gene were identified: 516G > T (allele frequency 0.25), 785A > G (0.3), 1138T > C (0.01), 64C > T (0.03), and 370C > T (0.01). The results showed significant differences in the concentration of EFV based on 516G > T, where the percentage of patients with supratherapeutic concentrations (> 4000 ng/mL) was higher among TT genotype carriers than among wild-type carriers (χ² = 17.00, p = 0.001); 71.43% of patients with the TT genotype had concentrations above 4000 ng/mL compared to only 10.34% of patients with the GG wild-type genotype. The data on the 785A > G variant show that 41.67% of GG carriers had concentrations above 4000 ng/mL, compared with only 12.24% of patients with the AA wild-type genotype. Discussion: CYP2B6 polymorphisms, specifically the 516G > T and 785A > G, had a major impact on the pharmacokinetics of EFV and therefore led to an increase in plasma concentrations of efavirenz among Yi HIV/AIDS patients. The results also support findings from other studies worldwide that associate these same polymorphisms with decreased enzyme activity and thus decreased ability to metabolize EFV. The unique genetic background of the Yi population underscores the importance of using pharmacogenomics tools specifically designed for this population. Conclusion: CYP2B6 polymorphisms, including specifically the 516G > T variant, are important predictors of plasma concentrations of EFV among Yi HIV positive patients. The 785A > G variant also predicts a higher percentage of patients exceeding the supratherapeutic range and does not affect median plasma concentrations. Dose adjustment guided by genotype may increase treatment response and decrease adverse events in this ethnic population. Clinical trial number: Not applicable.
SN - 1471-2334
ER -